Scribd
Upload
57 views1 page

DR Reddy's Is Planning To Conclude Phase 3 Trials of COVID-19 Vaccine Sputnik V by The End of March

Dr. Reddy's will conclude Phase 3 trials of the Sputnik V COVID-19 vaccine by the end of March 2021, having begun Phase 2 trials in the next few days. The company plans to finish Phase 2 trials by December 2020 and will forward the vaccine to India's Drug Controller General for approval once Phase 3 is complete. The Sputnik V vaccine works by mimicking COVID-19 infection to quickly build herd immunity and is based on a modified human adenovirus vector carrying the SARS-CoV-2 virus protein.

Uploaded by

MaPy TV
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
57 views1 page

DR Reddy's Is Planning To Conclude Phase 3 Trials of COVID-19 Vaccine Sputnik V by The End of March

Dr. Reddy's will conclude Phase 3 trials of the Sputnik V COVID-19 vaccine by the end of March 2021, having begun Phase 2 trials in the next few days. The company plans to finish Phase 2 trials by December 2020 and will forward the vaccine to India's Drug Controller General for approval once Phase 3 is complete. The Sputnik V vaccine works by mimicking COVID-19 infection to quickly build herd immunity and is based on a modified human adenovirus vector carrying the SARS-CoV-2 virus protein.

Uploaded by

MaPy TV
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
You are on page 1/ 1

Dr Reddy's Is Planning To Conclude

Phase 3 Trials of COVID-19 Vaccine


Sputnik V By The End Of March
CEO Erez Israeli said the Dr. Reddy’s would begin phase II trials in the
next few days and would complete phase III clinical trials of its Sputnik V
COVID-19 vaccine by March end. The Dr. Reddy’s Labs would forward the vaccine
for approval from the Drug Controller General of India (DCGI).

1,400 subjects for phase III, as compared to 100 participants for phase II trials.

Israeli said, “I hope we will finish phase II by December, which means not just the
enrolment and the trial but also compilations of results,"

This vaccine works by mimicking COVID-19 infection and will quickly build herd
immunity. SARS-CoV-2 virus is fairly stable which increases the viability of a
vaccine because there are no bio-chemical modifications.

Vaccines need to be tested on healthy people s and also on children, pregnant women
and the elderly separately. So rigorous testing is compulsory in this regard. It usually
takes five or ten years to make a vaccine. Data from India will be complemented by
the global clinical trial data of the vaccine.

The vaccine, Sputnik V, will be produced in India, at a third party site in Baddi.
Sputnik V vaccine is based on a modified human adenovirus as vector, which carries
the protein of the SARS-CoV-2 virus. RDIF says it will suppy 100 million doses to
India.

You might also like